Project description:High-resolution DNA methylation array analysis of human cancer samples and normal control tissue types Analisys of Differential Methylation Regions (DMRs) of human cancer samples and normal control tissue types performing high-resolution DNA methylation array analysis
Project description:Genomic imprinting is a form of epigenetic regulation that results in expression of either the maternally or paternally inherited allele of a subset of genes. Imprinted loci contain differentially methylated regions (DMRs) where cytosine methylation marks one of the parental alleles, providing cis-acting regulatory elements that influence the allelic expression of surrounding genes, however to date the total number of imprinted loci within the human genome is unknown. To characterize known imprinted DMRS and identify novel imprinted loci we have performed whole-genome bisulphite sequencing and high-resolution DNA methylation array analysis of healthy tissues. Sequencing of bisulfite converted DNA and array based analysis of normal tissues, human embryonic stem cells, androgenetic hydatidiform moles and leukocytes from reciprocal genome-wide uniparental disomies.
Project description:Epigenetic deregulation is a critical event in human malignancies. A number of DNA methylation markers are currently under evaluation as diagnostic and prognostic biomarkers for many cancers. However, its potential role in hepatocellular carcinoma (HCC) is under-explored. Aims: To develop a DNA methylation-based prognostic signature in surgically resected HCC Tumors from 224 HCC resected patients, 10 normal Liver individuals and 9 Cirrhotic patients were analyzed. Methylome profiling was done with Illumina HumanMethylation450 (485,000 CpG, 96% of known CpG islands). We selected probes in CpG islands located in promoters, hypermethylated (B value higher than 50%) in at least 5% of the tumors and hypomethylated (B value lower than 33%) in more than 90% of normal liver.
Project description:Genome wide DNA methylation profiling of normal and tumoral tissues of the breast. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 450 thousand CpGs in fresh frozen tissue samples (40 primary breast tumours and 17 normal breast tissues). Samples included morphologically normal samples of each tissue and tumor samples. Bisulphite converted DNA from the 57 samples were hybridised to the Illumina Infinium 450k Human Methylation Beadchip.
Project description:Epigenetics may help understanding the molecular mechanisms of atherosclerosis as genetic predisposition explains only part of cardiovascular disease risk. In particular, DNA methylation, a reversible and highly regulative DNA modification could contribute to disease onset and progression as it functions as effector for environmental impacts, including dietary and life-style, similarly to risk factors for cardiovascular diseases. We addressed this issue by performing whole-genome shotgun bisulfite sequencing and high-resolution DNAmethylation array analysis of healthy and diseased donor-matched atherosclerotic DNA methylomes. Sequencing of bisulfite converted DNA and array based analysis of atherosclerotic lesions and normal carotid tissue.
Project description:Genome-scale DNA methylation profiling using the Infinium DNA methylation BeadChip platform and samples from normal human eye and five ocular- related diseases DNA methylation analysis of eye samples from patient suffering ocular diseases (retinal detachment, diabetic retinopathy, glaucoma, uveal melanoma and retinoblastoma) using the Infinium DNA methylation BeadChip platform .
Project description:Systematic studies of the cancer genome are providing unprecedented insights into the molecular nature of human cancer. Using this information to guide the development and application of therapies in the clinic remains challenging. Here we report how cancer driving alterations detected in 11,215 tumors and 29 different tissues (integrating multiple omics) correlate with response to 265 compounds profiled in 1,001 cancer cell lines. We find that cell lines faithfully resemble tumours on the domain of these alterations, and numerous examples of altered genes and pathways conferring drug sensitivity and resistance. Significantly, logic-based modeling improves our ability to identify drug sensitive sub-types and machine-learning methods enable us to investigate the predictive ability of the different data-omics. We provide a comprehensive analysis of how somatic alterations identified from the large-scale analysis of primary tumors impact on drug response. This represents a rich resource to help identify therapeutic options for selected cancer populations. DNA was quantified by Quant-iT PicoGreen dsDNA Reagent (Invitrogen) and the integrity was analyzed in a 1.3% agarose gel. Bisulfite conversion of 600 ng of each sample was perform according to the manufacturer's recommendation for Illumina Infinium Assay. Effective bisulphite conversion was checked for three controls that were converted simultaneously with the samples. 4 ul of bisulfite converted DNA were used to hybridize on Infinium HumanMethylation 450 BeadChip, following Illumina Infinium HD Methylation protocol. Chip analysis was performed using Illumina HiScan SQ fluorescent scanner. The intensities of the images are extracted using GenomeStudio (2011.2) Methylation module (1.8.5) software. Methylation score of each CpG is represented as beta value. The cell lines are not treated with any drug or coumpound.
Project description:Whole genome bisulphite sequencing of 13 human cancer samples and 9 normal controls. The main goal is to find the Diffrenetial methylated regions (DMR) at Genome wide level in different tissues and cancer types Sequencing of bisulfite converted DNA human cancer samples and normal control tissue types.
Project description:We performed whole-genome methylation analysis using 450K Illumina BeadArrays on different human cell types. In total 24 experiments were performed. Dermal fibroblasts, three different epidermal melanocytes (dark, medium and light pigmentation), epidermal keratinocytes, mammary fibroblasts, mammary epithelial cells, mammary endothelial cells and mesenchymal stem cells were analyzed in technical duplicates. Unmethylated DNA were analyzed in technical duplicates. Two different normal breast tissue samples were analyzed. Finally peripheral blood leukocytes and an enzymatically methylated sample were analyzed. Genome-wide DNA methylation analysis of different cell types using Illumina Human Methylation 450K Beadchips.